SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ABTI Alpha-Beta Technology
ABTI 0.200+99,900.0%Jun 17 12:34 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Eduardo Canto who wrote (431)8/4/1997 1:39:00 PM
From: Tom D   of 572
 
The data are pathetic.

You and I both know how incredibly improbable these results are. If this was an election we'd conclude that it was fixed. Even if they can get FDA approval for the noncolorectal indication, the clinical significance of the efficacy is poor. Length of stay for placebo patients was 14.3 days, for 0.5 mg was 12.4 days, for 1 mg was 14.6 days. So why use the drug? ICU days = 3.7 for placebo, 3.3 for treated group. I do not think that clinicians, or insurance companies will pay much for this product. Even the mortality differences are not very impressive. Insurance companies will say that, at $2000 per course of therapy, the medicaiton is not cost-effective. I am sorry to say that I think that selling at 6 1/2 is a good idea. I have sold my stock and put it into DepoTech (DEPO).

The oncologic advisory committee of the FDA has their next meeting on September 18. The agenda has not been announced. There is a good chance that they will be assessing depocyt. These Phase III data are really exciting. The drug is being fast-tracked, with full approval expected in December of this year. If they don't assess depocyt in September, they surely will in their December meeting.

I think there is a much better return on DepoTech at $13 1/2 than ABTI at 6 1/2

TDD
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News